BioLine RX BLRX 深 滬
等待開盤 10-08 09:30:00 美东时间
2.205
-0.087
-3.80%
華盛通- 最 高2.3698
- 今 開2.28
- 成交量 2.40万股
- 最 低 2.16
- 昨 收 2.2922
- 總市值 1097.70万
- 52周最高 3.95
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 2.15
- 委 比 68.61%
- 總股本 497.82万
- 歷史最高 4122.00
- 量 比 1.27
- 振 幅 9.15%
- 歷史最低 2.15
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioLineRx And Hemispherian To Present Preclinical Efficacy Of GLIX1 In Orthotopic Glioblastoma Models, At 21st Meeting Of EANO 2026
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX...
09-10 19:11
BioLine Rx Q2 Sales $294.000K Miss $500.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $294.000 thousand which missed the analyst consensus estimate of $500.000 thousand by 41.20 percent. This is a 3.29 percent decrease over sales of $304.000 thousand the same period last year.
08-31 19:01
BioLineRx Announces $3.75M Registered Direct Offering Of ADSs At $2.78 Each And Concurrent Private Placement Of Warrants For Up To 2M ADSs
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Co...
08-28 20:03
BioLineRx And Hemispherian Announce New Preclinical Data Showing Strong Synergy Between GLIX1 And PARP Inhibitors In Patient-Derived Xenograft Model Of Ovarian Cancer
Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal dose GLIX1 in combination with olaparib also showed comparable efficacy to that se...
07-08 19:07
电话会总结 ｜ BioLineRx(BLRX)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据BioLineRx业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **2026年第一季度财务表现：** - **营收**：50万美元，主要来源于APHEXDA产品的特许权使用费收入 - **净亏损**：260万美元 - **研发费用**：250万美元 - **一般管理费用**：90万美元 - **非经营收入**：50万美元 - **现金及等价物**：季度末余额1,740万美元 ## 2. 财务指标变化 **同比变化（2026年Q1 vs 2025年Q1）：** - **营收增长**：从30万美元增至50万美元，同比增长66.7%，主要
05-30 12:27
BioLine Rx Q1 Sales $477.000K Beat $343.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $477.000 thousand which beat the analyst consensus estimate of $343.000 thousand by 39.07 percent. This is a 87.06 percent increase over sales of $255.000 thousand
05-27 19:02
BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade Gliomas
GBM remains one of the most aggressive and treatment-resistant cancers, urgently in need of breakthrough innovations and more effective treatment.In a comprehensive pre-clinical program, orally administered GLIX1
05-19 19:04
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers BioLine Rx (NASDAQ:BLRX) stock increased by 12.5% to $3.11 during Mond...
05-19 05:05
BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas
The GLIX1 program is being conducted under a collaboration between BioLineRx and Hemispherian announced in September 2025. The patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief
04-28 19:13
BioLineRx Launches First Human Trial For Brain Cancer Drug
BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase
03-26 19:17
